Laboratorios Farmaceuticos Rovi/€ROVI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos ROVI SA, ticker ROVI, is a Spain-based pharmaceutical company primarily engaged in developing, manufacturing, and commercializing pharmaceutical products. The company's activities span both domestic and international markets, focusing on a range of medical and drug treatments. Founded in 1946, ROVI continues to expand its reach and influence in the healthcare and pharmaceutical sectors.
- Ticker
- €ROVI
- Sector
- Health
- Primary listing
- BME
- Employees
- 2,470
- Headquarters
- Pozuelo de Alarcón, Spain
- Website
- www.rovi.es
ROVI Metrics
BasicAdvanced
€3.2B
17.19
€3.62
0.23
€0.78
1.25%
Price and volume
Market cap
€3.2B
Beta
0.23
52-week high
€86.20
52-week low
€53.00
Average daily volume
91K
Dividend rate
€0.78
Financial strength
Current ratio
2.054
Quick ratio
1.042
Long term debt to equity
0.112
Total debt to equity
0.15
Dividend payout ratio (TTM)
25.83%
Interest coverage (TTM)
37.80%
Profitability
EBITDA (TTM)
175.965
Gross margin (TTM)
64.73%
Net profit margin (TTM)
23.95%
Operating margin (TTM)
19.51%
Effective tax rate (TTM)
21.33%
Revenue per employee (TTM)
€310,000
Management effectiveness
Return on assets (TTM)
9.44%
Return on equity (TTM)
28.65%
Valuation
Price to earnings (TTM)
17.193
Price to revenue (TTM)
4.119
Price to book
4.57
Price to tangible book (TTM)
4.81
Price to free cash flow (TTM)
18.098
Free cash flow yield (TTM)
5.53%
Free cash flow per share (TTM)
3.44
Dividend yield (TTM)
1.25%
Forward dividend yield
1.25%
Growth
Revenue change (TTM)
3.21%
Earnings per share change (TTM)
39.93%
3-year revenue growth (CAGR)
-1.87%
10-year revenue growth (CAGR)
11.79%
3-year earnings per share growth (CAGR)
1.32%
10-year earnings per share growth (CAGR)
22.11%
3-year dividend per share growth (CAGR)
-9.49%
10-year dividend per share growth (CAGR)
21.31%
What the Analysts think about ROVI
Analyst ratings (Buy, Hold, Sell) for Laboratorios Farmaceuticos Rovi stock.
Analyst projections of the future price of Laboratorios Farmaceuticos Rovi stock.
Bulls say / Bears say
CDMO is becoming a stronger growth engine: first-half sales rose 38% to €106.3 million as Madrid operations recovered and the Phoenix facility began contributing. This growth broadens ROVI beyond its own medicines. (ROVI)
ROVI is adding capacity for a much larger contract-manufacturing business, with new plans for higher injectable production capacity and an ambition to reach about €700 million of CDMO sales by 2030. If it wins enough work to fill that capacity, it could create a substantial longer-term growth runway. (elEconomista)
Okedi sales rose 27% to €34 million in the first half, giving ROVI a growing branded-drug business alongside its manufacturing operations. Its momentum helped offset weakness elsewhere in specialty pharmaceuticals. (ROVI)
Heparin remains under pressure from lower partner orders as customers work through high inventories, alongside tougher price competition. ROVI still expects the low-molecular-weight heparin business to decline in 2026, despite improving its forecast to a mid-single-digit fall. (ROVI, StockAnalysis)
The first-half profit jump overstates the improvement in underlying trading: the €62.4 million Phoenix bargain-purchase gain was non-recurring, and EBITDA excluding it fell 10% year on year. That leaves profitability vulnerable if operating growth does not strengthen. (ROVI, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
ROVI Financial Performance
Revenues and expenses
ROVI Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ROVI
AllEURUSDGBP
Fund name | Fund size | €ROVI weighting |
|---|---|---|
Xtrackers Spain€XESD | €282M | 0.12% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.07% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.